Advertisement

Drugs

, Volume 79, Issue 3, pp 341–346 | Cite as

Sintilimab: First Global Approval

  • Sheridan M. HoyEmail author
AdisInsight Report
  • 277 Downloads

Abstract

Sintilimab (Tyvyt®) is a fully human IgG4 monoclonal antibody that binds to programmed cell death receptor-1 (PD-1), thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. It has been co-developed by Innovent Biologics and Eli Lilly and Company, and was recently approved in China for the treatment of classical Hodgkin’s lymphoma in patients who have relapsed or are refractory after ≥ 2 lines of systemic chemotherapy. Sintilimab is undergoing phase I, II and III development for use in various solid tumours, including non-small cell lung cancer and oesophageal cancer, in China. Phase I/II development of sintilimab for use in solid tumours is underway in the USA, with the US FDA accepting an Investigational New Drug application for sintilimab in January 2018. This article summarizes the milestones in the development of sintilimab leading to this first approval for the treatment of classical Hodgkin’s lymphoma in patients who have relapsed or are refractory after ≥ 2 lines of systemic chemotherapy.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Merryman RW, Armand P, Wright KT, et al. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 2017;1(26):2643–54.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–15.CrossRefPubMedGoogle Scholar
  4. 4.
    Innovent Biologics. China’s NMPA approves Innovent’s anti-PD-1 antibody Tyvyt® (sintilimab injection) for Hodgkin’s lymphoma [media release]. 26 Dec 2018. http://innoventbio.com/en/#/news/123.
  5. 5.
    Innovent Biologics. Tyvyt® (sintilimab): Chinese prescribing information. Suzhou: Innovent Biologics; 2019.Google Scholar
  6. 6.
    Innovent Biologics. Innovent receives an approval from the US FDA to initiate clinical trials for its anti-CD47 monoclonal antibody IBI-188 [media release]. 29 Sept 2018. http://innoventbio.com/en/#/news/111.
  7. 7.
    Eli Lilly and Company. Lilly and Innovent Biologics announce a strategic alliance to bring potential oncology therapies to patients in China and around the world [media release]. 20 Mar 2015. http://lilly.mediaroom.com/.
  8. 8.
    Eli Lilly and Company. Lilly and Innovent Biologics expand their strategic alliance to include immuno-oncology bispecific antibodies in China and globally [media release]. 11 Oct 2015. http://lilly.mediaroom.com/.
  9. 9.
    Innovent Biologics. Innovent announces global collaboration with Hutchison MediPharma to evaluate combination of sintilimab and fruquintinib in solid tumors [media release]. 29 Nov 2018. http://innoventbio.com/en/#/news/119.
  10. 10.
    Zhang S, Zhang M, Wu W, et al. Preclinical characterization of sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antibody Ther. 2018;1(2):65–73.Google Scholar
  11. 11.
    Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Xu JM, Jia R, Wang Y, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors [abstract no. e15125]. J Clin Oncol. 2018;36(15 Suppl).Google Scholar
  13. 13.
    Jia R, Li YL, Jin YS, et al. Efficacy and safety of anti-PD-1 antibody (IBI308) in treating advanced neuroendocrine neoplams [abstract no. 2143]. Neuroendocrinology. 2018;106(Suppl 1):230.Google Scholar
  14. 14.
    Ying K, Xu N, Jiang H, et al. Efficacy and safety of sintilimab combined with 1st line chemotherapy in advanced squamous cell non-small cell lung cancer [abstract no. OA08]. J Thorac Oncol. 2018;13 (12 Suppl):S1047.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations